搜索结果

Search Results for " purvalanol b "

Targets Recommended: CDK Parasite

抑制剂 & 化合物

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T7167	Purvalanol B NG 95,(2R)-2-[[6-[(3-氯-4-羧基苯基)氨基]-9-(1-甲基乙基)-9H-嘌呤-2-基]氨基]-3-甲基-1-丁醇	CDK; Parasite	Cell Cycle/Checkpoint; Microbiology/Virology
	Purvalanol B (NG 95) 是选择性可逆的 ATP 竞争性 CDK 抑制剂。它在一系列其他蛋白激酶 (IC50>1000 nM) 中显示出对 CDK 的选择性。它抑制耐氯喹菌株 P. falciparum 的生长。
T13454	(S)-Purvalanol B (S)-NG 95	BCL	Apoptosis
	(S)-Purvalanol B 是 Purvalanol B 的 S 对映体，Purvalanol B 是一种细胞周期蛋白依赖性激酶（CDK）抑制剂。
T2059	Purvalanol A NG-60	Apoptosis; CDK; Autophagy	Apoptosis; Autophagy; Cell Cycle/Checkpoint
	Purvalanol A (NG-60) 是一种CDK 抑制剂，对 cdc2-cyclin B、cdc2-cyclin B、cdk2-cyclin E、cdk4-cyclin D1 和 cdk5-p35 的IC50值分别为 4、70、35、850 和 75 nM。
T71231	VMY-1-101	Others	Others
	VMY-1-101 is a synthesized fluorescent CDK inhibitor. VMY-1-101 demonstrates potent CDK inhibitory activity, enhanced induction of G2/M arrest and modest apoptosis as compared to purvalanol B.
T71230	VMY-1-103	Others	Others
	VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2)/M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death ...

化合物

Purvalanol B

Cat.No: T7167

Synonym: NG 95,(2R)-2-[[6-[(3-氯-4-羧基苯基)氨基]-9-(1-甲基乙基)-9H-嘌呤-2-基]氨基]-3-甲基-1-丁醇

Target: CDK, Parasite

(S)-Purvalanol B

Cat.No: T13454

Synonym: (S)-NG 95

Target: Apoptosis, CDK, Autophagy

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPK-01413	H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) H-2K,OVA,MHC,H2-K1	Mouse	HEK293 Cells
	Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se...
TMPK-01412	HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) SARS-CoV-2 epitope,MHC	Human	HEK293 Cells
	HLA-B15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype.
TMPK-01416	HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated MHC,SARS-CoV-2 epitope	Human	HEK293 Cells
	HLA-B15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype.